The Best Quantum Computing Stocks to Buy in 2026

The article highlights IBM and IonQ as early quantum-computing plays, with IBM expected to grow revenue and EPS at 5% CAGRs from 2025 to 2028 and IonQ’s revenue projected to rise from $130 million in 2025 to $600 million by 2028. IBM’s quantum business is still limited financially, but it could be folded into hybrid cloud and AI services, while IonQ offers higher upside through more scalable trapped-ion systems. Overall tone is constructive on the sector, but the piece is largely long-term commentary rather than a near-term market catalyst.

Analysis

The market is still pricing quantum as a science project, but the real investable angle is platform distribution: the winner will be whoever can attach quantum compute to an existing enterprise workflow and monetize it as an add-on rather than a standalone SKU. That favors IBM near term because it already owns the customer relationship, procurement channels, and hybrid-cloud stack; quantum becomes an embedded feature that can lift retention and enterprise wallet share before it becomes a meaningful P&L line item. In other words, the optionality is less about quantum revenue in the next 2-3 years and more about reducing churn and increasing attach rates across software and services.

IONQ’s upside is more convex, but the market is likely overestimating how quickly technical superiority converts into durable enterprise share. Accuracy and room-temperature operation matter, yet the bottleneck over the next several years is not just hardware performance — it is workflow integration, developer tooling, and whether customers trust the ecosystem enough to build around it. That means government and research spend can carry the story for a while, but commercial scaling likely arrives in lumpy steps, not a smooth adoption curve.

The second-order beneficiary is not the obvious semiconductor names but the picks-and-shovels layer around cloud distribution, AI orchestration, and enterprise software integration; quantum that is accessed via cloud APIs is effectively a usage-based software product, not a hardware sale. The main loser is any pure-play competitor without a software moat or installed base, because even if its device is better on paper, procurement friction and support burden slow conversion. The contrarian risk is that IBM’s quantum narrative may be too incremental to matter to valuation, while IONQ’s multiple leaves little room for execution hiccups, dilution, or a funding reset if commercialization slips by even 12-18 months.

Key Decisions for Investors

• Long IBM vs short IONQ in a 6-12 month pair: IBM offers lower execution risk and better downside support from cash flows/dividend, while IONQ’s valuation embeds a much steeper commercialization curve; target is relative outperformance if quantum remains a narrative rather than a revenue driver.
• For a tactical upside expression, buy IBM 12-18 month call spreads on any pullback: the thesis is not quantum beta alone, but multiple expansion if management frames quantum as an enterprise attach layer to hybrid cloud/AI; risk is limited if the market keeps paying ~20x forward earnings.
• Avoid initiating fresh IONQ longs ahead of earnings or guidance events unless you can tolerate dilution risk; if you want exposure, use smaller size or call spreads only, because the stock can re-rate sharply lower on any schedule slip or capex/intensity surprise.
• Relative-value basket: long IBM / short a basket of unprofitable quantum pure plays if available, to isolate the premium the market is paying for distribution and balance-sheet resilience over technical purity.
• Watch for partner announcements with hyperscalers or government agencies over the next 3-9 months; those are the catalysts that can convert quantum from optionality into monetizable workload and would be the highest-conviction entry point for IONQ.